Search - tctmd.com

Displaying 921 - 940 of 1075

Sort: Relevancy | Date

Presentation TCT 2016

Saudi Arabia Presents: A Case When TAVR Crashes

Presenter: Juan F. Granada, Oscar A. Mendiz, Khaled F Al-Shaibi

November 01, 2016

Presentation TCT 2016

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Presenter: Neil E. Moat, John G. Webb, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Presenter: Neil E. Moat, John G. Webb, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Presenter: Neil E. Moat, John G. Webb, Marina Urena

October 31, 2016

Presentation TCT 2016

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Presenter: Neil E. Moat, John G. Webb, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

Presenter: Neil E. Moat, John G. Webb, Alexandra J. Lansky

October 31, 2016

Presentation TCT 2016

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Presenter: Neil E. Moat, John G. Webb, Adam B. Greenbaum

October 31, 2016

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Presentation TCT 2016

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Presenter: Neil E. Moat, John G. Webb, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Complications of Structural Heart Disease Intervention

Presenter: George S. Hanzel, Mauricio G. Cohen

October 31, 2016

Presentation TCT 2016

Case #2: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Augusto D. Pichard

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Presenter: Michael J. Mack, Ralph Stephan von Bardeleben, Neil E. Moat

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Case #1: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Advertisement

Saudi Arabia Presents: A Case When TAVR Crashes

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Complications of Structural Heart Disease Intervention

Case #2: A TAVR Complication to Learn From

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Case #1: A TAVR Complication to Learn From

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content